Who are Anti-TNF Therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Etanercept (ETN), Enbrel (etanercept), etanercept (EnbrelTM), Biological: Etanercept and its biosimilars, Tapered doses of TNFi, Switch to a second anti-TNF drug alone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-tnf-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Anti-TNF Therapy — Competitive Intelligence Brief

Anti-TNF Therapy (Anti-TNF Therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF inhibitor. Area: Immunology.

marketed TNF inhibitor TNF (Tumor Necrosis Factor) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Anti-TNF Therapy (Anti-TNF Therapy) — Takeda. Anti-TNF therapy blocks tumor necrosis factor (TNF), a key inflammatory cytokine that drives immune-mediated inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Anti-TNF Therapy TARGET	Anti-TNF Therapy	Takeda	marketed	TNF inhibitor	TNF (Tumor Necrosis Factor)
Etanercept (ETN)	Etanercept (ETN)	University of Leeds	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-alpha (TNF) and TNF-beta (lymphotoxin-alpha)
Enbrel (etanercept)	Enbrel (etanercept)	Pfizer	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-alpha (TNF) and TNF-beta (lymphotoxin-alpha)
etanercept (EnbrelTM)	etanercept (EnbrelTM)	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	TNF receptor antagonist (TNF inhibitor)	TNF-α and TNF-β (tumor necrosis factor)
Biological: Etanercept and its biosimilars	Biological: Etanercept and its biosimilars	Hanyang University Seoul Hospital	marketed	TNF receptor antagonist / TNF inhibitor	TNF-α and TNF-β
Tapered doses of TNFi	Tapered doses of TNFi	University Health Network, Toronto	marketed	TNF inhibitor (tapered dosing strategy)	TNF-alpha
Switch to a second anti-TNF drug alone	Switch to a second anti-TNF drug alone	Védrines, Philippe, M.D.	marketed	TNF inhibitor (class-level; specific agent varies)	TNF-alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF inhibitor class)

University Hospital, Montpellier · 2 drugs in this class
Amgen · 1 drug in this class
Biogen · 1 drug in this class
Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class
National Eye Institute (NEI) · 1 drug in this class
Abbott · 1 drug in this class
Spanish Clinical Pharmacology Society · 1 drug in this class
Takeda · 1 drug in this class
University Health Network, Toronto · 1 drug in this class
University Hospital, Ghent · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti-TNF Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-tnf-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab